UCB

Contact
ucb-group.com
+3225599999

UCB S.A.

Allée de la Recherche, 60
1070 Brüssel
Belgium
+3225599999
ucb-group.com
Contact
Profile News
Contact

About UCB

UCB is a global biopharmaceutical company, with a focus on neurology and immunology. We support patient groups who provide valuable services to patient communities and understand what matters to people living with severe diseases.

Read more about UCB
Facts about UCB
  • Focus : Manufacturer
  • Industry : Pharma

News about UCB

UCB

21-Oct-2016 | business & finance

Evotec and UCB sign multi-year CNS pharmacology agreement

Evotec AG announced a collaboration with UCB to provide a broad range of in vitro pharmacology services. Under the terms of the three-year agreement, ...

Read news
UCB

25-Feb-2016 | science

Major pharma companies sign up to groundbreaking Parkinson's consortium

Seven of the world's largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and ...

Read news
UCB

11-Feb-2016 | science

UCB and Baylor College of Medicine launch strategic alliance in neurodegeneration

Strategic collaboration to discover transformational therapies for neurodegenerative disease

Read news
UCB

30-Jul-2015 | research and development

UCB announces Phase 3 clinical trial program for epratuzumab in Systemic Lupus Erythematosus did not meet primary endpoint

UCB announced that the two EMBODY™ Phase 3 clinical studies for epratuzumab in Systemic Lupus Erythematosus (SLE) did not meet their primary clinical ...

Read news
UCB

07-Apr-2015 | business & finance

UCB to focus on core business in India

UCB to sell its established brands portfolio in India to Dr. Reddy’s for € 118 million

Read news
UCB

31-Mar-2015 | business & finance

UCB secures multimillion pound funding boost from UK Government

UCB announced that its joint bid with five other UK-based organisations has been selected as a recipient of the Government’s 2014 Advanced Manufacturing ...

Read news
UCB

13-Jan-2015 | research and development

Dermira and UCB announce start of Phase 3 program for CIMZIA® (certolizumab pegol) in psoriasis

Dermira, Inc. and UCB announced that the first patients have been dosed in the Phase 3 clinical program designed to evaluate the efficacy and safety of ...

Read news
UCB

07-Jan-2013 | research and development

Neupro approved in Japan for Parkinson’s disease and Restless Legs Syndrome

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Neupro® (rotigotine transdermal patch) for the treatment of Parkinson’s disease (PD ...

Read news
Show more news about UCB

Here you will find UCB S.A.